ADAM to Launch Human Trials of 3D-Printed Bone

long bones

ADAM, a startup company that 3D prints bone, plans to complete pre-clinical trials within the month and commence first human trials by the end of 2019. ADAM, which stands for Advanced Development of Additive Manufacturing, seeks to reduce the cost for synthetic bone production by half. The company is pursuing commercial launch of its core technology in 2020.

A.D.A.M. employs calcium-based minerals to print bones, which are made to measure based on patients’ CT scans. The 3D-printed implants stimulate natural bone growth and gradually biodegrade, eventually being replaced by the patient’s bone tissue. This process obviates the need to take a graft from another bone or bone donor.

Low production costs could enable transplant accessibility to thousands of people each year who delay or forego surgery due to high costs or lack of graft material.

ADAM is also developing Digital Body Atlases. These would allow individuals to take a proactive rather than reactive response to bone damage by having a complete body scan on hand to serve as a blueprint for repair as needed.

Project CEO Volodymyr Usov said, “It’s definitely time to reshape our attitude towards bodies and find new solutions. We are confident that we are doing the right thing for all people, and that is the strongest motivation.”

ADAM, which has offices in Connecticut and Ukraine, has already secured partnerships with ARMI, Stanley Black & Decker and Big Pharma.

JAV

Julie A. Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

RELATED ARTICLES



CONTACT BONEZONE

 

CONTACT BONEZONE